ST吉药(300108) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 196,294,346.82, a year-on-year increase of 2.41%[9] - Net profit attributable to shareholders was CNY 26,314,909.43, a slight decrease of 0.09% compared to the same period last year[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses dropped by 78.20% to CNY 4,856,311.10[9] - Basic earnings per share remained unchanged at CNY 0.04, while diluted earnings per share also stayed at CNY 0.04[9] - Weighted average return on equity decreased by 7.04% to 1.32% for the reporting period[9] - Total operating revenue for Q3 2018 was CNY 196,294,346.82, an increase of 1.6% compared to CNY 191,671,075.82 in the same period last year[41] - Net profit for Q3 2018 reached CNY 27,951,547.15, representing a 4.4% increase from CNY 26,830,780.89 in Q3 2017[43] - The company reported a total profit of ¥129,026,705.36, up from ¥127,959,067.18, showing a growth of approximately 0.8%[54] - The total comprehensive income for the current period was ¥103,242,672.21, compared to ¥102,532,640.67 in the previous period, reflecting a marginal increase of 0.7%[55] Assets and Liabilities - Total assets increased by 24.35% to CNY 3,922,822,725.02 compared to the end of the previous year[9] - Total liabilities increased to CNY 1,898,275,140.23 from CNY 1,205,893,207.64[33] - Total equity rose to CNY 2,024,547,584.79 from CNY 1,948,751,985.34[33] - Accounts receivable increased by 43.69% to CNY 656,808,451.93 from CNY 457,093,577.48 due to higher sales and expanded consolidation scope[21] - Other receivables rose by 246.40% to CNY 51,423,807.26 from CNY 14,845,041.61, primarily due to increased deposits and receivables[21] - Long-term equity investments amounted to CNY 68,999,700.00, including CNY 67,062,500.00 in Jilin Haitong Pharmaceutical Co., Ltd.[21] - Construction in progress increased by 187.32% to CNY 566,943,765.35 from CNY 197,322,400.87, mainly due to investments in the construction of Meihekou Xinhua Hospital[21] - Goodwill increased by 81.16% to CNY 518,228,401.22 from CNY 286,061,692.34, resulting from the acquisition of Liaoning Meiluo Pharmaceutical Co., Ltd. and Zhejiang Yalida Capsule Co., Ltd.[21] Cash Flow - Cash flow from operating activities decreased by 59.93% to CNY 25,220,474.30 year-to-date[9] - Cash inflow from operating activities totaled 617,092,507.65, an increase from 514,928,773.68 in the previous period[63] - Net cash flow from operating activities was 25,220,474.30, down from 62,939,193.54 in the previous period[65] - Cash outflow from investing activities was 521,802,463.06, compared to 138,565,041.19 in the previous period[67] - Net cash flow from investing activities was -458,185,851.03, worsening from -136,265,041.19 in the previous period[67] - Cash inflow from financing activities was 753,409,000.00, up from 306,093,000.00 in the previous period[67] - Net cash flow from financing activities was 253,571,287.03, compared to 58,671,931.32 in the previous period[67] - The ending balance of cash and cash equivalents was 190,452,186.01, an increase from 152,926,923.40 in the previous period[67] - The company reported a net decrease in cash and cash equivalents of -179,394,089.70, compared to -14,653,916.33 in the previous period[67] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,206[13] - The largest shareholder, Lu Zhongkui, holds 23.92% of the shares, amounting to 159,278,980 shares[13] Government Subsidies - The company received government subsidies amounting to CNY 56,252,312.75, which positively impacted non-recurring gains[10] Financial Expenses - Financial expenses rose by 57.57% to CNY 39,210,763.15 from CNY 24,885,292.40, attributed to increased interest expenses from bank loans[22] - Financial expenses totaled ¥39,210,763.15, compared to ¥24,885,292.40 in the previous period, indicating a significant increase of about 57.3%[54] Research and Development - Research and development expenses increased to ¥7,956,285.71 from ¥6,508,910.06, marking a rise of approximately 22.3%[52]